Logo

AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receive MHLW’s Approval for Advanced Liver and Non-Small Cell Lung Cancers

Share this

AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receive MHLW’s Approval for Advanced Liver and Non-Small Cell Lung Cancers

Shots:

  • The MHLW has approved Imfinzi & Imjudo for liver, biliary tract & lung cancers. Imfinzi + Imjudo approved for unresectable HCC & NSCLC in combination with CT; Imfinzi for unresectable HCC as monotx. & for BTC
  • The approval was based on the results from the P-III trials (HIMALAYA & TOPAZ-1) published in NEJM & the P-III trial (POSEIDON) in the Journal of Clinical Oncology. In (HIMALAYA)/(POSEIDON)/(TOPAZ-1) trials, a reduction in risk of death (22%/23%/24% after 6.5mos. of follow-up), patients were alive in the combination therapy vs CT (31% vs 20% after 3yrs./33% vs 22% @2yrs./23.6% vs 11.5% @2yrs.), respectively
  • The safety profiles of the combination therapy & Imfinzi as monotx. were consistent with known profiles of each medicine with no new safety signals in all trials

Ref: AstraZeneca  | Image: AstraZeneca

Related News:- AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receive the US FDA’s Approval for Metastatic Non-Small Cell Lung Cancer

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions